An Objective Approach to Deriving the Clinical Performance of Autoverification Limits
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study describes an objective approach to deriving the clinical performance of autoverification rules to inform laboratory practice when implementing them. Anonymized historical laboratory data for 12 biochemistry measurands were collected and Box-Cox-transformed to approximate a Gaussian distribution. The historical laboratory data were assumed to be error-free. Using the probability theory, the clinical specificity of a set of autoverification limits can be derived by calculating the percentile values of the overall distribution of a measurand. The 5th and 95th percentile values of the laboratory data were calculated to achieve a 90% clinical specificity. Next, a predefined tolerable total error adopted from the Royal College of Pathologists of Australasia Quality Assurance Program was applied to the extracted data before subjecting to Box-Cox transformation. Using a standard normal distribution, the clinical sensitivity can be derived from the probability of the Z-value to the right of the autoverification limit for a one-tailed probability and multiplied by two for a two-tailed probability. The clinical sensitivity showed an inverse relationship with between-subject biological variation. The laboratory can set and assess the clinical performance of its autoverification rules that conforms to its desired risk profile.
Abstract
This study describes an objective approach to deriving the clinical performance of autoverification rules to inform laboratory practice when implementing them. Anonymized historical laboratory data for 12 biochemistry measurands were collected and Box-Cox-transformed to approximate a Gaussian distribution. The historical laboratory data were assumed to be error-free. Using the probability theory, the clinical specificity of a set of autoverification limits can be derived by calculating the percentile values of the overall distribution of a measurand. The 5th and 95th percentile values of the laboratory data were calculated to achieve a 90% clinical specificity. Next, a predefined tolerable total error adopted from the Royal College of Pathologists of Australasia Quality Assurance Program was applied to the extracted data before subjecting to Box-Cox transformation. Using a standard normal distribution, the clinical sensitivity can be derived from the probability of the Z-value to the right of the autoverification limit for a one-tailed probability and multiplied by two for a two-tailed probability. The clinical sensitivity showed an inverse relationship with between-subject biological variation. The laboratory can set and assess the clinical performance of its autoverification rules that conforms to its desired risk profile.
참고문헌 (19)
- Shih MC, "Building and validating an autoverification system in the clinical chemistry laboratory", Lab Med, 42, pp.668~673 (2011)
- Randell EW, "Autoverification of test results in the core clinical laboratory", Clin Biochem, 73, pp.11~25 (2019)
- Feitosa MS, "Implementation of criteria for automatic release of clinical chemistry test results in a laboratory at an academic public hospital", J Bras Patol Med Lab, 52, pp.149~156 (2016)
- van Rossum HH, "An approach to selecting auto-verification limits and validating their error detection performance independently for pre-analytical and analytical errors", Clin Chim Acta, 508, pp.130~136 (2020)
- Fraser CG, "Biological variation data are necessary prerequisites for objective autoverification of clinical laboratory data", Accredit Qual Assur, 7, pp.455~460 (2002)
- Tan RZ, "Optimized delta check rules for detecting misidentified specimens in children", Am J Clin Pathol, 153, pp.605~612 (2020)
- Markus C, "Evidence-based approach to setting delta check rules", Crit Rev Clin Lab Sci, 58, pp.49~59 (2021)
- Tan RZ, "Impact of delta check time intervals on error detection capability", Clin Chem Lab Med, 58, pp.384~389 (2020)
- Tan RZ, "Relationship between biological variation and delta check rules performance", Clin Biochem, 80, pp.42~47 (2020)
- Tan RZ, "An approach to optimize delta checks in test panels–the effect of the number of rules included", Ann Clin Biochem, 57, pp.215~222 (2020)
- Badrick T, "Patient-based real-time quality control : review and recommendations", Clin Chem, 65, pp.962~971 (2019)
- Badrick T, "Implementation of patient-based real-time quality control", Crit Rev Clin Lab Sci, 57, pp.532~547 (2020)
- Badrick T, "A primer on patient-based quality control techniques", Clin Biochem, 64, pp.1~5 (2019)
- Loh TP, "Recommendation for performance verification of patient-based real-time quality control", Clin Chem Lab Med, 58, pp.1205~1213 (2020)
- Liu J, "Verification of out-of-control situations detected by"average of normal"approach", Clin Biochem, 49, pp.1248~1253 (2016)
- "Box-Cox Normality Plot (v.1.1.12) in Free Statistics Software, Office for Research Development and Education. 2016" (2021)[URL]
- "Chemical pathology analytical performance specifications" (2021)[URL]
- Loh TP, "Setting minimum clinical performance specifications for tests based on disease prevalence and minimum acceptable positive and negative predictive values : practical considerations applied to COVID-19 testing", Clin Biochem, 88, pp.18~22 (2021)
- Krasowski MD, "Autoverification in a core clinical chemistry laboratory at an academic medical center", J Pathol Inform, 5, pp.13~ (2014)